Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since the onset of the 2009 pandemic, several observational public health investigations in Canada have identified evidence that suggests that adults, particularly younger adults, who have previously received seasonal influenza vaccine are at increased risk of infection with the 2009 pandemic strain of H1N1 (pH1N1). Investigations in Australia, the United States and the United Kingdom have not identified this effect. While it is not possible to have an answer to whether this affect is real prior to the second wave of the 2009 pandemic, it remains vital to future influenza vaccination programs that the hypothesis that, in 2009, seasonal vaccine increases or decreases the risk of pH1N1 infection be confirmed or refuted.
The objective of this study is to determine whether Ontario adults aged 18-60 years who receive the 2009 seasonal influenza vaccine will be at a 2 fold or greater increased risk of infection with influenza pH1N1 during the second or third wave of the 2009 pandemic.
This study will be an observer -blind randomized controlled trial.
This study will primarily recruit patients from an existing cohort of adult health care and other workers in Toronto, as of September 15, 2009, almost 1000 adults are participating in this cohort; with approximately 75 new cohort members being recruited weekly (target is 1300). Recruitment will be supplemented by enrollment at Hamilton Health Sciences Centre (N~3920 employees plus physicians & midwives) and Queen Elizabeth II Health Centre in Halifax (N~6000 employees plus physicians & midwives).
To date, health care workers in the Toronto cohort have been recruited at the Mount Sinai Hospital, Toronto East General Hospital, and North York General Hospital. Recruitment is just beginning at Sunnybrook Health Sciences Centre, and the University Health Network.
Non-health care workers are being recruited from several large Toronto employers of primarily office workers. These include the Ontario Agency for Health Protection and Promotion, the head offices of the Ontario Power Generation Corporation, the Art Gallery of Ontario, and the head offices of Scotia Bank. Non-health care workers should meet inclusion criteria and should not work primarily with children or from a home office.
Participants in the study are completing web-based diaries weekly, and, whenever they develop symptoms possibly compatible with influenza, are submitting nasal swabs, and completing symptom diaries daily while ill. Nasal swabs are tested by polymerase chain reaction (PCR) on a same or next day basis with antivirals prescribed to participants who develop influenza.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Seasonal influenza vaccination | Experimental | Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification |
|
| Placebo | Placebo Comparator | 0.5 mL normal saline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fluviral influenza vaccine, 2009-2010 | Biological | 0.5 mL intramuscular |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab | Influenza infection (pH1N1) as diagnosed by PCR from self-collected mid-turbinate swab. Participant is asked to collect a swab when they have symptoms possibly compatible with an acute viral respiratory illness: 1) fever without another obvious source, 2) at least two new respiratory symptoms (runny or stuffy nose, sneezing, sore or scratchy throat, hoarseness, cough), or 3) one respiratory symptom (as above) and one systemic symptom (fever, malaise, muscle aches, headache, fatigue) | day +7 post seasonal influenza vaccination (or placebo) to end of study |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Allison J McGeer, MD | MOUNT SINAI HOSPITAL | Principal Investigator |
| Brenda L. Coleman, PhD | MOUNT SINAI HOSPITAL | Principal Investigator |
| Natasha Crowcroft, MD | Ontario Agency for Health Protection & Promotion | Principal Investigator |
| Karen Green, MSc | MOUNT SINAI HOSPITAL | Study Director |
| Kevin Katz, MD | North York General Hospital | Study Director |
| Mark Loeb, MD | Hamilton Health Sciences Centre | Study Director |
| Donald Low, MD | MOUNT SINAI HOSPITAL | Study Director |
| Shelly McNeil, MD | Queen Elizabeth II Health Sciences Centre | Study Director |
| Matthew Muller, MD, PhD | Unity Health Toronto | Study Director |
| Andrew Simor, MD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| North York General Hospital | North York | Ontario | M2K 1E1 | Canada | ||
| Mount Sinai Hospital |
Not provided
Enrolment start: October 5, 2009 Enrolment complete: February 3, 2010
Enrolment was conducted from a variety of work places and university settings.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Seasonal Influenza Vaccination | Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification |
| FG001 | Placebo | 0.5 mL normal saline |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Seasonal Influenza Vaccination | Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification |
| BG001 | Placebo | 0.5 mL normal saline |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab | Influenza infection (pH1N1) as diagnosed by PCR from self-collected mid-turbinate swab. Participant is asked to collect a swab when they have symptoms possibly compatible with an acute viral respiratory illness: 1) fever without another obvious source, 2) at least two new respiratory symptoms (runny or stuffy nose, sneezing, sore or scratchy throat, hoarseness, cough), or 3) one respiratory symptom (as above) and one systemic symptom (fever, malaise, muscle aches, headache, fatigue) | Posted | Number | 95% Confidence Interval | participants | day +7 post seasonal influenza vaccination (or placebo) to end of study |
|
Enrolment to March 28, 2010 - Maximum: 6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Seasonal Influenza Vaccination | Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| death | Congenital, familial and genetic disorders | MedDRA (10.0) | Systematic Assessment | Not related to study drug |
Not provided
A major limitation to this study was the date of enrolment for the subjects: only 249 (53%) of the subjects were enrolled by the end of second wave of the pandemic (and a third wave did not occur before the end of the study).
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Brenda Coleman | Mount Sinai Hospital | 416-586-4800 | 4161 | bcoleman@mtsinai.on.ca |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Normal saline | Biological | 0.5 mL intramuscular |
|
| Sunnybrook Health Sciences Centre |
| Study Director |
| Toronto |
| Ontario |
| M5G 1X5 |
| Canada |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 |
| Placebo |
0.5 mL normal saline |
|
|
|
| 1 |
| 234 |
| 0 |
| 234 |
| EG001 | Placebo | 0.5 mL normal saline | 1 | 234 | 0 | 234 |
|
| pneumonia | Respiratory, thoracic and mediastinal disorders | MedDRA (10.0) | Systematic Assessment |
|
Not provided
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |